Supply Chain Archives
01/27/2026
Establish Stability from the Start with Frozen Starting Materials for Cell Therapy Development
For many years, cell therapy programs defaulted to fresh leukapheresis-derived starting material. The assumption was that if you could minimize the time from collection to manufacturing, you would maximize viability. As a result, fresh apheresis became not only a scientific preference but an operational tradition, shaping how clinical teams would schedule donors, how manufacturing suites would allocate capacity, and how programs would structure day-to-day execution. Program leaders treated any deviation from “fresh” as a risk to be justified rather than a choice to be evaluated. But reality keeps getting in the way.
01/27/2026
How Defragmenting the Pre-Clinical Supply Chain De-Risks Downstream Operations
Every stage of the supply chain including cryopreservation, logistics, and BioServices and biostorage, must align to ensure a seamless transition from pre-clinical work into Phase I trials. However, early-stage teams often select multiple vendors who each handle one piece of the process because it feels faster or more cost-effective in the moment. This approach, however, builds fragmented supply chains that introduce gaps as programs scale. And when those gaps surface, teams must devote valuable time and effort simply to get back on track.
12/22/2025
Celebrating Innovation at the Cryoport Systems Grand Opening in Louvres, France
Cryoport Systems recently opened the doors of its newest Global Supply Chain Center (GSCC) in Louvres, France, marking a major step forward in how cell and gene therapies move safely and compliantly across Europe and the world. Strategically located just outside Paris and minutes from Charles de Gaulle Airport (CDG), this GSCC strengthens our integrated network and brings critical capabilities closer to sponsors, CROs, CDMOs, and clinical sites throughout the region, and strengthens our support of regional animal health and reproductive medicine organizations.
12/16/2025
Driving Compliance and Standardization in CGT Supply Chains
As cell and gene therapies (CGTs) continue to advance and more therapies reach late-stage clinical trials and commercialization, the complexity of the related logistics is only increasing. Therapies are crossing borders, reaching broader patient populations, and expanding into global distribution, all of which introduces risk if standards are inconsistent. Compliance and standardization, as a result, are essential for ensuring both scalability and patient safety.
12/11/2025
Setting the Benchmark for Quality in Cell and Gene Therapy Logistics
Quality in cell and gene therapy (CGT) is the foundation that determines whether a therapy reaches a patient intact and effective. As the industry increasingly scales from early development of CGTs to global commercialization, the margin for error narrows as volume and complexity increase. Standards like ISO 21973 provide a framework, but true industry leadership comes from how those standards are applied. In this, Cryoport Systems is setting that benchmark.
12/09/2025
What is ISO 21973 and Why It Matters for Cell and Gene Therapy
Cell and gene therapies (CGTs) are transforming medicine, but the complexity of these treatments introduces new challenges for supply chain management. Every shipment represents a therapy that could change or save a life, which is a level of responsibility that demands precision and transparency, as well as standards that leave absolutely no room for error. ISO 21973:2020 was created to meet that need.
12/08/2025
Scaling for What’s Next in EMEA
As the advanced therapy medicinal products (ATMP) sector continues to expand across Europe and beyond, the infrastructure supporting these therapies needs to evolve just as quickly. Cryoport Systems is doing exactly that by scaling capabilities, deepening partnerships, and investing in new infrastructure to meet the growing needs of therapy developers.
11/17/2025
How Global Shifts are Reshaping ATMP Logistics Beyond Borders
As advanced therapy medicinal products (ATMPs) continue to gain traction globally, the logistics required to move these therapies across borders are facing unprecedented challenges. From shifting trade policies to regional conflicts and Brexit legacy issues, global events are reshaping how therapies are distributed... and how supply chains must adapt in real time.
10/28/2025
